Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2019-05729 | Registry Identifier | CTRP (Clinical Trial Reporting Program) | |
| R34HL142322 | U.S. NIH Grant/Contract | View source | |
| 10304 | Other Identifier | Fred Hutch/University of Washington Cancer Consortium |
Not provided
Not provided
Not provided
The federal funding period ended. The study was originally intended to be multi-site but was only conducted at the lead site. Due to the rarity of the subject population & smaller # of enrolling sites, we were not able to reach accrual goals.
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
Not provided
Not provided
Not provided
Not provided
This phase II trial studies the side effects of a cord blood transplant using dilanubicel and to see how well it works in treating patients with human immunodeficiency virus (HIV) positive hematologic (blood) cancers. After a cord blood transplant, the immune cells, including white blood cells, can take a while to recover, putting the patient at increased risk of infection. Dilanubicel consists of blood stem cells that help to produce mature blood cells, including immune cells. Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Total body irradiation is a type of whole-body radiation. Giving chemotherapy and total-body irradiation before a cord blood transplant with dilanubicel may help to kill any cancer cells that are in the body and make room in the patient's bone marrow for new stem cells to grow and reduce the risk of infection.
OUTLINE: Patients are assigned to 1 of 2 regimens.
REGIMEN A: Patients receive fludarabine intravenously (IV) over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6, and undergo total body irradiation (TBI) twice daily (BID) on days -4 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.
REGIMEN B: Patients receive fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo TBI once daily (QD) on days -2 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 28, 80, and 180 days, and then at 1 and 2 years.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Regimen A (fludarabine, cyclophosphamide, TBI, dilanubcel) | Experimental | Patients receive fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6, and undergo TBI BID on days -4 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity. |
|
| Regimen B (anticancer drugs, TBI, dilanubicel) | Experimental | Patients receive fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo TBI QD on days -2 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fludarabine | Drug | Given IV |
|
| Measure | Description | Time Frame |
|---|---|---|
| Primary Graft Failure Rejection | Will be defined by no neutrophil recovery by day 45 (regardless of donor chimerism) or autologous recovery (neutrophil recovery but < 10% donor chimerism in blood and bone marrow) by day 36. This outcome was originally intended to be assessed for per the aforementioned definitions, but was only able to be assessed through 35 days post-transplant. | Up to day 35 post-transplant |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Infusion Toxicities | Defined as Common Terminology Criteria for Adverse Events version 5.0 grade >= 3 events. | Within the first 24 hours after infusion |
| Median Number of Days Post-Transplant to Neutrophil Recovery Occurred |
Not provided
Inclusion Criteria:
>= 6 months to =< 65 years
Treatment with combination antiretroviral therapy (cART) for at least 1 month before enrollment
Viral load < 5000 copies/ml plasma on cART
Disease criteria
Acute myeloid leukemia
Acute lymphoblastic leukemia
Chronic myelogenous leukemia excluding refractory blast crisis. To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylate
Myelodysplasia (MDS) International Prognostic Scoring System (IPSS) intermediate (Int)-2 or high risk (i.e., refractory anemia with excess blasts [RAEB], refractory anemia with excess blasts in transformation [RAEBt]) or refractory anemia with severe pancytopenia or high-risk cytogenetics. Blasts must be < 10% by a representative bone marrow aspirate morphology
Other hematologic malignancy such as non-Hodgkin lymphomas. Fred Hutch site: These patients must be presented at Patient Care Conference (PCC) prior to enrollment, given potential competing eligibility on auto-transplant protocols. Participating centers: These patients must be discussed with the lead principal investigator, Filippo Milano prior to enrollment
Karnofsky (>= 16 years old) >= 70%
Lansky (< 16 years old) >= 50%
Adults: Calculated creatinine clearance must be > 60 mL and serum creatinine =< 2 mg/dL
Children (< 18 years old): Calculated creatinine clearance must be > 60 mL/min
Total serum bilirubin must be < 3 mg/dL
Transaminases must be < 3 x the upper limit of normal
Diffusion capacity of the lung for carbon monoxide (DLCO) corrected > 50% normal or for pediatric patients in whom DLCO cannot be measured has adequate pulmonary function
Left ventricular ejection fraction > 45% OR
Shortening fraction > 26%
Ability to understand and the willingness to sign a written informed consent document (adult subject or parent/legal guardian of minor subject)
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Filippo Milano | Fred Hutch/University of Washington Cancer Consortium | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California San Francisco | San Francisco | California | 94143 | United States | ||
| Children's National Medical Center |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Regimen A (Fludarabine, Cyclophosphamide, TBI, Followed by Unmanipulated Cord Blood and Dilanubicel) | Patients receive fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6, and undergo TBI BID on days -4 to -1 (totaling 1320 cGy). Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity. Fludarabine: Given IV Cyclophosphamide: Given IV Total-Body Irradiation: Undergo TBI Umbilical Cord Blood Transplantation: Undergo UCBT Dilanubicel: Given IV |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jul 12, 2023 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cyclophosphamide | Drug | Given IV |
|
|
| Thiotepa | Drug | Given IV |
|
|
| Total-Body Irradiation | Radiation | Undergo TBI |
|
|
| Umbilical Cord Blood Transplantation | Procedure | Undergo UCBT |
|
|
| Dilanubicel | Biological | Given IV |
|
|
Neutrophil recovery is defined as the first day of 2 consecutive days of absolute neutrophil count >= 500 after the first post-cord blood transplant nadir. This outcome was originally intended to be assessed for up to 45 days post-transplant, but was only able to be assessed through 35 days post-transplant.
| Up to Day 35 post-transplant |
| Platelet Engraftment | Will be defined as the first day of a platelet count > 20,000/ul with subsequent transfusions for 7 days. This outcome was originally intended to be assessed for up to 2 years post-transplant, but was only able to be assessed through 35 days post-transplant. | 35 days post-transplant |
| Incidence of Severe (Grades III-IV) Acute Graft Versus Host Disease (GVHD) | Will be defined by the 2014 National Institutes of Health (NIH) criteria. This outcome was originally intended to be assessed for up to 2 years post-transplant, but was only able to be assessed through 35 days post-transplant. | 35 days post-transplant |
| Incidence of Chronic GVHD | Will be defined by the 2014 NIH criteria. This outcome was originally intended to be assessed for up to 2 years post-transplant, but was only able to be assessed through 35 days post-transplant. | 35 days post-transplant |
| Incidence of Non-relapse Mortality | Will be defined as death without a prior relapse. This outcome was originally intended to be assessed for up to 180 days post-transplant, but was only able to be assessed through 35 days post-transplant. | 35 days post-transplant |
| Human Immunodeficiency Virus (HIV) Plasma Viral Load | Assess CCR5Δ32 cord blood stem cell engraftment and its effect on biomarkers of HIV-1 infection, including plasma viral load and replication-competent reservoirs, as well as in gut and other sites (if tissue samples are available). This outcome was originally intended to be assessed weekly for up to 2 years post-transplant, but was only able to be assessed through 35 days post-transplant. | Baseline and weekly to 35 days post-transplant |
| Immune Homeostasis | Concentration of immunity cells per microliters after transplant | Up to 2 years |
| Immune Reconstitution | Concentration of immunity cells per microliters after transplant | Up to 2 years |
| Change in HIV-1 Induced Inflammatory Immune Responses | HIV viral load by PCR (copies per milliliter; mL) | Up to 2 years |
| HIV Rebound Following Antiretroviral Therapy (ART) Cessation | Count of participants with HIV rebound, measured by HIV viral load by PCR (copies per milliliter; mL) | Up to 2 years |
| Viral Kinetics Following ART Cessation | HIV viral load by PCR (copies per milliliter; mL) | Up to 2 years |
| Washington D.C. |
| District of Columbia |
| 20010 |
| United States |
| Case Western Reserve University | Cleveland | Ohio | 44106 | United States |
| Cleveland Cord Blood Center | Cleveland | Ohio | 44128 | United States |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | United States |
| FG001 | Regimen B (Anti-cancer Drugs Plus TBI, Followed by Unmanipulated Cord Blood and Dilanubicel) | Patients receive fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo TBI QD on days -2 to -1 (totaling 400 cGy). Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity. Fludarabine: Given IV Cyclophosphamide: Given IV Thiotepa: Given IV Total-Body Irradiation: Undergo TBI Umbilical Cord Blood Transplantation: Undergo UCBT Dilanubicel: Given IV |
| COMPLETED |
|
| NOT COMPLETED |
|
There were no participants enrolled to Regimen A of the study.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Regimen A (Fludarabine, Cyclophosphamide, TBI, Followed by Unmanipulated Cord Blood and Dilanubicel) | Patients receive fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6, and undergo TBI BID on days -4 to -1 (totaling 1320 cGy). Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity. Fludarabine: Given IV Cyclophosphamide: Given IV Total-Body Irradiation: Undergo TBI Umbilical Cord Blood Transplantation: Undergo UCBT Dilanubicel: Given IV |
| BG001 | Regimen B (Anti-cancer Drugs Plus TBI, Followed by Unmanipulated Cord Blood and Dilanubicel) | Patients receive fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo TBI QD on days -2 to -1 (totaling 400 cGy). Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity. Fludarabine: Given IV Cyclophosphamide: Given IV Thiotepa: Given IV Total-Body Irradiation: Undergo TBI Umbilical Cord Blood Transplantation: Undergo UCBT Dilanubicel: Given IV |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Median | Full Range | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
| ||||||||||||||||||
| Matched cord blood unit with either homozygous or heterozygous CCR5Δ32 mutation. | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Primary Graft Failure Rejection | Will be defined by no neutrophil recovery by day 45 (regardless of donor chimerism) or autologous recovery (neutrophil recovery but < 10% donor chimerism in blood and bone marrow) by day 36. This outcome was originally intended to be assessed for per the aforementioned definitions, but was only able to be assessed through 35 days post-transplant. | No participants were enrolled to Regimen A of the study. | Posted | Count of Participants | Participants | Up to day 35 post-transplant |
|
|
| |||||||||||||||||||||||||||||
| Secondary | Incidence of Infusion Toxicities | Defined as Common Terminology Criteria for Adverse Events version 5.0 grade >= 3 events. | No participants were enrolled to Regimen A of the study. | Posted | Number | infusion toxicity events | Within the first 24 hours after infusion |
| |||||||||||||||||||||||||||||||
| Secondary | Median Number of Days Post-Transplant to Neutrophil Recovery Occurred | Neutrophil recovery is defined as the first day of 2 consecutive days of absolute neutrophil count >= 500 after the first post-cord blood transplant nadir. This outcome was originally intended to be assessed for up to 45 days post-transplant, but was only able to be assessed through 35 days post-transplant. | No participants were enrolled to Regimen A of the study. | Posted | Median | Full Range | Days post-transplant | Up to Day 35 post-transplant |
| ||||||||||||||||||||||||||||||
| Secondary | Platelet Engraftment | Will be defined as the first day of a platelet count > 20,000/ul with subsequent transfusions for 7 days. This outcome was originally intended to be assessed for up to 2 years post-transplant, but was only able to be assessed through 35 days post-transplant. | No participants were enrolled to Regimen A of the study. The single Regimen B participant did not achieve platelet engraftment prior to death on Day +35 post-transplant. | Posted | Count of Participants | Participants | 35 days post-transplant |
| |||||||||||||||||||||||||||||||
| Secondary | Incidence of Severe (Grades III-IV) Acute Graft Versus Host Disease (GVHD) | Will be defined by the 2014 National Institutes of Health (NIH) criteria. This outcome was originally intended to be assessed for up to 2 years post-transplant, but was only able to be assessed through 35 days post-transplant. | No participant was enrolled to Regimen A of the study. | Posted | Number | Number of Grade 3/4 aGVHD Events | 35 days post-transplant |
| |||||||||||||||||||||||||||||||
| Secondary | Incidence of Chronic GVHD | Will be defined by the 2014 NIH criteria. This outcome was originally intended to be assessed for up to 2 years post-transplant, but was only able to be assessed through 35 days post-transplant. | No participants were enrolled to Regimen A of the study. | Posted | Number | Number of cGVHD Events | 35 days post-transplant |
| |||||||||||||||||||||||||||||||
| Secondary | Incidence of Non-relapse Mortality | Will be defined as death without a prior relapse. This outcome was originally intended to be assessed for up to 180 days post-transplant, but was only able to be assessed through 35 days post-transplant. | No participants were enrolled to Regimen A of the study. | Posted | Count of Participants | Participants | 35 days post-transplant |
| |||||||||||||||||||||||||||||||
| Secondary | Human Immunodeficiency Virus (HIV) Plasma Viral Load | Assess CCR5Δ32 cord blood stem cell engraftment and its effect on biomarkers of HIV-1 infection, including plasma viral load and replication-competent reservoirs, as well as in gut and other sites (if tissue samples are available). This outcome was originally intended to be assessed weekly for up to 2 years post-transplant, but was only able to be assessed through 35 days post-transplant. | No participants were enrolled to Regimen A of the study. | Posted | Number | percentage of viral load change | Baseline and weekly to 35 days post-transplant |
| |||||||||||||||||||||||||||||||
| Secondary | Immune Homeostasis | Concentration of immunity cells per microliters after transplant | No participants survived until 2 years, so outcome could not be measured. | Posted | Up to 2 years |
| |||||||||||||||||||||||||||||||||
| Secondary | Immune Reconstitution | Concentration of immunity cells per microliters after transplant | No participants survived until 2 years, so outcome could not be measured. | Posted | Up to 2 years |
| |||||||||||||||||||||||||||||||||
| Secondary | Change in HIV-1 Induced Inflammatory Immune Responses | HIV viral load by PCR (copies per milliliter; mL) | No participants survived until 2 years, so outcome could not be measured. | Posted | Up to 2 years |
| |||||||||||||||||||||||||||||||||
| Secondary | HIV Rebound Following Antiretroviral Therapy (ART) Cessation | Count of participants with HIV rebound, measured by HIV viral load by PCR (copies per milliliter; mL) | No participants survived until 2 years, so outcome could not be measured. | Posted | Up to 2 years |
| |||||||||||||||||||||||||||||||||
| Secondary | Viral Kinetics Following ART Cessation | HIV viral load by PCR (copies per milliliter; mL) | No participants survived until 2 years, so outcome could not be measured. | Posted | Up to 2 years |
|
Assessed from start of conditioning until participant death on study at Day 35 post-transplant.
Adverse events were routinely assessed via standard of care clinic visits with laboratory assessments.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Regimen A (Fludarabine, Cyclophosphamide, TBI, Followed by Unmanipulated Cord Blood and Dilanubicel) | Patients receive fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6, and undergo TBI BID on days -4 to -1 (totaling 1320 cGy). Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity. Fludarabine: Given IV Cyclophosphamide: Given IV Total-Body Irradiation: Undergo TBI Umbilical Cord Blood Transplantation: Undergo UCBT Dilanubicel: Given IV | 0 | 0 | 0 | 0 | 0 | 0 |
| EG001 | Regimen B (Anti-cancer Drugs Plus TBI, Followed by Unmanipulated Cord Blood and Dilanubicel) | Patients receive fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo TBI QD on days -2 to -1 (totaling 400 cGy). Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity. Fludarabine: Given IV Cyclophosphamide: Given IV Thiotepa: Given IV Total-Body Irradiation: Undergo TBI Umbilical Cord Blood Transplantation: Undergo UCBT Dilanubicel: Given IV | 1 | 1 | 1 | 1 | 1 | 1 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hepatobiliary disorders - Other, Liver insufficiency | Hepatobiliary disorders | CTCAE (5.0) | Systematic Assessment | Liver insufficiency |
|
| Renal and urinary disorders - Other, Renal insufficiency | Renal and urinary disorders | CTCAE (5.0) | Systematic Assessment | Renal insufficiency |
|
| Posterior Reversible Encephalopathy Syndrome (PRES) | Nervous system disorders | CTCAE (5.0) | Systematic Assessment | PRES |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Sepsis (Strep mitis + Strep salivarius + Staph sp.) | Infections and infestations | CTCAE (5.0) | Systematic Assessment |
| |
| Mucositis oral | Gastrointestinal disorders | CTCAE (5.0) | Systematic Assessment |
| |
| Acute kidney injury (AKI) | Renal and urinary disorders | CTCAE (5.0) | Systematic Assessment | AKI |
|
| Myocardial infarction | Cardiac disorders | CTCAE (5.0) | Systematic Assessment |
|
The study was originally intended to be multi-site but ended up only being conducted at the lead site. Due to the rarity of the subject population and the smaller number of enrolling sites, we were not able to reach accrual goals. Once the funding period ended, the study had to be closed to accrual.
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Filippo Milano | Fred Hutchinson Cancer Center | 206.667.5925 | fmilano@fredhutch.org |
| Oct 8, 2024 |
| Prot_SAP_001.pdf |
| ICF | No | No | Yes | Informed Consent Form | Sep 28, 2022 | May 31, 2024 | ICF_000.pdf |
Not provided
| ID | Term |
|---|---|
| D004915 | Leukemia, Erythroblastic, Acute |
| D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| D007947 | Leukemia, Megakaryoblastic, Acute |
| D015470 | Leukemia, Myeloid, Acute |
| D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| D019337 | Hematologic Neoplasms |
| D015658 | HIV Infections |
| D009190 | Myelodysplastic Syndromes |
| D000754 | Anemia, Refractory, with Excess of Blasts |
| D008228 | Lymphoma, Non-Hodgkin |
| D000753 | Anemia, Refractory |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009196 | Myeloproliferative Disorders |
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007945 | Leukemia, Lymphoid |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009371 | Neoplasms by Site |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D000740 | Anemia |
| D008223 | Lymphoma |
Not provided
Not provided
| ID | Term |
|---|---|
| C024352 | fludarabine |
| C042382 | fludarabine phosphate |
| D003520 | Cyclophosphamide |
| D013852 | Thiotepa |
| D014916 | Whole-Body Irradiation |
| D036101 | Cord Blood Stem Cell Transplantation |
| ID | Term |
|---|---|
| D010752 | Phosphoramide Mustards |
| D009588 | Nitrogen Mustard Compounds |
| D009150 | Mustard Compounds |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D063088 | Phosphoramides |
| D009943 | Organophosphorus Compounds |
| D013721 | Triethylenephosphoramide |
| D001388 | Aziridines |
| D001389 | Azirines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
| D008919 | Investigative Techniques |
| D033581 | Stem Cell Transplantation |
| D017690 | Cell Transplantation |
| D064987 | Cell- and Tissue-Based Therapy |
| D001691 | Biological Therapy |
| D014180 | Transplantation |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
| >=65 years |
|
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|